QL09
Impact of Ocrelizumab in MS Patients on Fatigue: Preliminary Results
Multiple Sclerosis (MS) is a chronic inflammatory-neurodegenerative disease of the central nervous system characterized by myriad and variable symptoms in working age adults; however, fatigue is a very prevalent and debilitating symptom of the disease in many aspects of patients' lives. MS fatigue itself is associated with clinical disability and can predict disease progression. Previous work has focused on quantifying fatigue with the Modified Fatigue Impact Scale (MFIS) being a validated measure used in People with Multiple Sclerosis (PwMS). In the age of novel therapeutics previous work has looked at the impact of newer Disease Modifying Treatments (DMT) on patient's MS fatigue scores. While studies thus far have not shown an effect of DMT on MS fatigue with the advent of Ocrelizumab a fully humanized monoclonal antibody against CD20 expressing B-cells with higher rates of No Evidence of Disease Activity (NEDA) compared to interferon therapy this question must be readdressed.
Objectives:
Our aim is to evaluate patient's MS Fatigue using the validated MFIS at initiation of treatment with Ocrelizumab, at 6 months, and 1 year. Our hypothesis is that higher efficacious therapies such as Ocrelizumab will demonstrate decreased subjective fatigue scores on the MFIS.
Methods:
This is a retrospective single center study of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Progressive Multiple Sclerosis (PPMS) patients followed in University of Florida MS fatigue clinic and receiving Ocrelizumab therapy. Patients are asked to perform MFIS at baseline and every 6 months within the fatigue clinic. In addition, patient demographics, disease characteristics, and concomitant therapies for fatigue will be collected. Statistical analysis will occur overall from baseline to 6 months, 6 months to 1 year and baseline to 1 year.
Results:
Results will be updated at time of presentation.
Conclusions:
The authors surmise that highly efficacious disease modifying treatment with Ocrelizumab could impact patient's subjective fatigue scores as rated by the MFIS.